Navigation Links
NASDAQ Gives Dynatronics a Second Three-Month Extension for Minimum Bid Price Compliance
Date:12/29/2008

SALT LAKE CITY, Dec. 29 /PRNewswire-FirstCall/ --Dynatronics Corporation (Nasdaq: DYNT) today announced that a second temporary grace period extension, filed by NASDAQ with the SEC, gives the company until approximately June 28, 2009, to comply with NASDAQ's $1 per share minimum bid rule.

"We are pleased that NASDAQ has further extended the timeframe for compliance in light of the current market environment," stated Kelvyn H. Cullimore Jr., chairman and president of Dynatronics. "This will give us time to realize the impact of operating improvements that are emerging in part because of our recent agreement with Vici Capital, a private operations consulting firm that is assisting Dynatronics in identifying significant changes that we can implement to improve our bottom line over the next year."

In addition, Dynatronics' newly expanded catalog released in September is positively impacting sales, generating improved margins through adjusted product pricing.

"We are also facilitating greater order flow from our domestic dealers through an adaptation of our DynaClub direct sales program. This promises to be a source of increased revenue over the coming year as dealers embrace the benefits of this program," Cullimore continued. "We believe all of these improvements, together with the more than $2 million in annual expense reductions we have previously implemented, should restore profitability and build investor confidence in owning our stock."

Dynatronics manufactures, markets and distributes advanced-technology medical devices, orthopedic soft goods and supplies, treatment tables and rehabilitation equipment for the physical therapy, sports medicine, chiropractic, podiatry, plastic surgery, dermatology and other related medical, cosmetic and aesthetic markets. More information regarding Dynatronics is available at www.dynatronics.com.

This press release contains forward-looking statements. Those statements include references to the company's expectations and include specifically the reference in this press release to increased revenues through the DynaClub direct sales program and the reference to restoring profitability. Such statements are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Actual results may vary from the views expressed in the forward-looking statements contained in this release. The development and sale of the company's products are subject to a number of risks and uncertainties, including, but not limited to, changes in the regulatory environment, competitive factors, inventory risks due to shifts in market demand, market demand for the company's products, availability of financing at cost effective rates, and the risk factors listed from time to time in the company's SEC reports including, but not limited to, the report on Form 10-K for the year ended June 30, 2008.


'/>"/>
SOURCE Dynatronics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. BELLUS Health announces formal notice to voluntarily delist from NASDAQ
2. Memory Pharmaceuticals Regains Compliance with NASDAQ Market Capitalization Requirement
3. Mylan Announces Move to NASDAQ Stock Market
4. DATATRAK International, Inc. Receives Notice from NASDAQ
5. BELLUS Health is Preparing to Voluntarily Delist from the NASDAQ Capital Market
6. Memory Pharmaceuticals Receives NASDAQ Decisions
7. PAREXEL International to Present at NASDAQ OMX 22nd Investor Program
8. Keryx Biopharmaceuticals Receives Nasdaq Notification
9. Accuray Receives Nasdaq Notification Related to the Late Filing of Form 10-Q
10. BELLUS Health Announces Stock Listing Transfer from NASDAQ Global Market to NASDAQ Capital Market
11. Pharmos Corporation Announces Receipt of Nasdaq Noncompliance Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... Texas (PRWEB) , ... August 16, 2017 , ... Ten ... Credit Union's Stars in the Classroom and will win a visit by a Houston ... grades K-12 who are at least five years old can visit texanschecking.com/stars to nominate ...
(Date:8/16/2017)... ATLANTA, Georgia (PRWEB) , ... August 16, 2017 ... ... practice in Atlanta, opened their doors. They celebrate 30 years in business this ... to create an up-to-date, inviting, tranquil space to serve their patients. , ...
(Date:8/16/2017)... ... August 16, 2017 , ... Maury Regional Health has announced a ... By broadly deploying AccuVein devices, Maury Regional Medical Center is making vein visualization part ... of a needle stick and more importantly, helps our staff members locate a vein ...
(Date:8/16/2017)... New Cumberland, PA (PRWEB) , ... August 16, 2017 , ... ... announced today it has successfully opened clubfoot clinics in all 29 Indian states—bringing the ... its newest clinic in Kangra, Himachal Pradesh, the nonprofit organization is on track to ...
(Date:8/16/2017)... ... August 16, 2017 , ... Fusion Flix Inc., a Telly ... over four countries and millions of viewers in a partnership with the Amazon Video ... On-Demand and fully available on Blu Ray disc in 2018. Proceeds will be going ...
Breaking Medicine News(10 mins):
(Date:7/31/2017)... -- Three Tru-D SmartUVC robots have arrived at Brian Allgood ... Tru-D, short for "Total Room Ultraviolet Disinfection," is a 5-foot-5 germ-killing robot ... (ES) professional cleans the area with traditional cleaning protocols. ... Tru-D fights germs at Army hospitals ... "Although the BAACH has a very low infection rate, ...
(Date:7/27/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported ... The Company reported second quarter net sales of $1.954 ... period, and an increase of 2.1% on a constant ... from the LDR Holding Corporation acquisition, second quarter 2017 ... or 0.3% on a constant currency basis. ...
(Date:7/26/2017)... BEACH, Fla. , July 26, 2017 ... of enrollment of our clinical trial evaluating Altemia TM ... Cell Anemia (SCA) and Sickle Cell Disease (SCD). The ... to evaluate the efficacy and safety of Altemia TM ... trial is conducted under US IND 125274. ...
Breaking Medicine Technology: